SymBio Pharmaceuticals Limited
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
SymBio Pharmaceuticals Limited made a loss over the last year. SymBio Pharmaceuticals Limited owes ¥1.31 for every ¥1 it owns. SymBio Pharmaceuticals Limited made a loss in each of the last two years.
Compared with Healthcare companies in Japan · latest annual results Dec 2025.
P/E ratio
LossSymBio Pharmaceuticals Limited made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
-6.46SymBio Pharmaceuticals Limited's book value is negative (it owes more than it owns), so P/B is not meaningful.
Market cap
¥3.8 BThe total market value of all of SymBio Pharmaceuticals Limited's shares at today's price (share price × number of shares), smaller than 84% of Healthcare companies in Japan. PosiCap size class: Micro Cap.
Net worth (book value)
NegativeSymBio Pharmaceuticals Limited's net worth is negative (¥583 M below zero, balance sheet 30 Jun 2026): it owes more than it owns, so book value per share and P/B are not meaningful.
Return on equity (ROE)
-677.1%SymBio Pharmaceuticals Limited lost 677.1% of its shareholders' money over the last year, lower than almost all Healthcare companies in Japan.
Owes vs Owns
1.31×SymBio Pharmaceuticals Limited owes ¥1.31 for every ¥1 it owns, so it owes more than it owns, higher than almost all Healthcare companies in Japan.
Dividend yield
NoneSymBio Pharmaceuticals Limited does not currently pay a dividend.
Revenue growth
-47%Revenue fell 47% in the year to Dec 2025, and shrank 49% a year on average over 3 years.
Profit growth
LossSymBio Pharmaceuticals Limited made a loss in each of the last two years.
Profit margin
-365.3%SymBio Pharmaceuticals Limited lost ¥365 for every ¥100 of revenue.
Interest cover
Not coveredSymBio Pharmaceuticals Limited's operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashSymBio Pharmaceuticals Limited held ¥901 M more cash than debt (net cash) at Dec 2025.
Questions
What is SymBio Pharmaceuticals Limited's return on equity?
SymBio Pharmaceuticals Limited lost 677.1% of its shareholders' money over the last year, lower than almost all Healthcare companies in Japan.
How much does SymBio Pharmaceuticals Limited owe compared with what it owns?
SymBio Pharmaceuticals Limited owes ¥1.31 for every ¥1 it owns, so it owes more than it owns, higher than almost all Healthcare companies in Japan.
Does SymBio Pharmaceuticals Limited pay a dividend?
No. SymBio Pharmaceuticals Limited does not currently pay a dividend.
Is SymBio Pharmaceuticals Limited's revenue growing?
Revenue fell 47% in the year to Dec 2025, and shrank 49% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.